|
1
|
Lyon: Eurocim version 4.0. European
incidence database V2.3, 730 entity dictionary. European Network of
Cancer Registries. 2001.
|
|
2
|
Ljungberg B, Bensalah K, Bex A, Canfield
S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, et
al: Guidelines on Renal Cell Carcinoma. Eur Assoc Urol. 2014.
|
|
3
|
Ljungberg B, Campbell SC, Choi HY, Jacqmin
D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal
cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Macleod LC, Hotaling JM, Wright JL,
Davenport MT, Gore JL, Harper J and White E: Risk factors for renal
cell carcinoma in the VITAL study. J Urol. 190:1657–1661. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Znaor A, Lortet-Tieulent J, Laversanne M,
Jemal A and Bray F: International variations and trends in renal
cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shuch B, Amin A, Armstrong AJ, Eble JN,
Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI and Kutikov A:
Understanding pathologic variants of renal cell carcinoma:
Distilling therapeutic opportunities from biologic complexity. Eur
Urol. 67:85–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schmidinger M: Improving outcomes in
metastatic clear cell renal cell carcinoma by sequencing therapy.
American Society of Clinical Oncology educational book/ASCO.
American Society of Clinical Oncology. Meeting. pp. e228–e238.
2014;
|
|
10
|
Dranitsaris G, Schmitz S and Broom RJ:
Small molecule targeted therapies for the second-line treatment for
metastatic renal cell carcinoma: A systematic review and indirect
comparison of safety and efficacy. J Cancer Res Clin Oncol.
139:1917–1926. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Escudier B, Albiges L and Sonpavde G:
Optimal management of metastatic renal cell carcinoma: Current
status. Drugs. 73:427–438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schnadig ID, Hutson TE, Chung H, Dhanda R,
Halm M, Forsyth M and Vogelzang NJ: Dosing patterns, toxicity, and
outcomes in patients treated with first-line sunitinib for advanced
renal cell carcinoma in community-based practices. Clin Genitourin
Cancer. 12:413–421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim S, Ding W, Zhang L, Tian W and Chen S:
Clinical response to sunitinib as a multitargeted tyrosine-kinase
inhibitor (TKI) in solid cancers: A review of clinical trials. Onco
Targets Ther. 7:719–728. 2014.PubMed/NCBI
|
|
14
|
Poprach A, Pavlik T, Melichar B, Kubackova
K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, et
al: Clinical and laboratory prognostic factors in patients with
metastatic renal cell carcinoma treated with sunitinib and
sorafenib after progression on cytokines. Urol Oncol. 32:488–495.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dudek AZ, Zolnierek J, Dham A, Lindgren BR
and Szczylik C: Sequential therapy with sorafenib and sunitinib in
renal cell carcinoma. Cancer. 115:61–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krusch M, Salih J, Schlicke M, Baessler T,
Kampa KM, Mayer F and Salih HR: The kinase inhibitors sunitinib and
sorafenib differentially affect NK cell antitumor reactivity in
vitro. J Immunol. 183:8286–8294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Terme M, Ullrich E, Delahaye NF, Chaput N
and Zitvogel L: Natural killer cell-directed therapies: Moving from
unexpected results to successful strategies. Nat Immunol.
9:486–494. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Geisler K, Reischer A, Kroeger I, Jacobs
B, Meinhardt K, Bauer R, Ryffel B, Mackensen A and Ullrich E:
Nilotinib combined with interleukin-2 mediates antitumor and
immunological effects in a B16 melanoma model. Oncol Rep.
31:2015–2020. 2014.PubMed/NCBI
|
|
19
|
Krieg S and Ullrich E: Novel immune
modulators used in hematology: Impact on NK cells. Front Immunol.
3:3882013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mignot G, Ullrich E, Bonmort M, Ménard C,
Apetoh L, Taieb J, Bosisio D, Sozzani S, Ferrantini M, Schmitz J,
et al: The critical role of IL-15 in the antitumor effects mediated
by the combination therapy imatinib and IL-2. J Immunol.
180:6477–6483. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Claus M, Greil J and Watzl C:
Comprehensive analysis of NK cell function in whole blood samples.
J Immunol Methods. 341:154–164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Powles T, Chowdhury S, Bower M, Saunders
N, Lim L, Shamash J, Sarwar N, Sadev A, Peters J and Green J: The
effect of sunitinib on immune subsets in metastatic clear cell
renal cancer. Urol Int. 86:53–59. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kondo T, Nakazawa H, Ito F, Hashimoto Y,
Osaka Y, Futatsuyama K, Toma H and Tanabe K: Favorable prognosis of
renal cell carcinoma with increased expression of chemokines
associated with a Th1-type immune response. Cancer Sci. 97:780–786.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Olive C, Cheung C, Nicol D and Falk MC:
Expression of cytokine mRNA transcripts in renal cell carcinoma.
Immunol Cell Biol. 76:357–362. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Onishi T, Ohishi Y, Goto H, Tomita M and
Abe K: An assessment of the immunological status of patients with
renal cell carcinoma based on the relative abundance of T-helper 1-
and -2 cytokine-producing CD4+ cells in peripheral blood. BJU Int.
87:755–759. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fehniger TA, Cooper MA, Nuovo GJ, Cella M,
Facchetti F, Colonna M and Caligiuri MA: CD56bright natural killer
cells are present in human lymph nodes and are activated by T
cell-derived IL-2: A potential new link between adaptive and innate
immunity. Blood. 101:3052–3057. 2003. View Article : Google Scholar : PubMed/NCBI
|
